• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, October 18, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

HIV ‘drug factory’ implant promises once-a-year therapy

Bioengineer by Bioengineer
December 5, 2022
in Science News
Reading Time: 3 mins read
0
OMID VEISEH
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

HOUSTON – (Dec. 5, 2022) – A Rice University laboratory, with a boost from the Bill & Melinda Gates Foundation,will develop a once-a-year treatment for patients infected with HIV and other infectious diseases.

OMID VEISEH

Credit: Jeff Fitlow/Rice University

HOUSTON – (Dec. 5, 2022) – A Rice University laboratory, with a boost from the Bill & Melinda Gates Foundation,will develop a once-a-year treatment for patients infected with HIV and other infectious diseases.

The Rice lab of bioengineer Omid Veiseh has received a $3 million foundation grant to develop implants that produce and deliver monoclonal anti-HIV antibody (mAb) therapeutics for at least a year. Michael Diehl, an associate professor of bioengineering and chemistry at Rice, is co-investigator on the grant. 

The project joins Veiseh’s other implantable therapies that promise to treat cancer, Type 1 diabetes and injuries caused by heart attacks through encapsulated “drug factories.” 

These employ cells engineered to make therapeutic substances — in this case, mAbs — to be delivered to patients through protective biopolymer shells. Veiseh said these cell-protecting capsules could be adapted to deliver combination therapies for multiple infectious diseases.

“We’re starting to tackle diseases like HIV and malaria because their complexity, how therapy has to be administered and the cost mean many parts of the world don’t benefit from biologic therapeutics,” said Veiseh, an assistant professor of bioengineering who came to Rice in 2017 with a recruitment grant from the Cancer Prevention and Research Institute of Texas.

“What’s fascinating is that biologics are made by cells, but manufactured in giant bioreactors,” he said. “A lot of cost and effort goes into purifying the biologic you want, to stabilize it and ultimately put it in a vial which then has to be shipped and administered to the patient. 

“Our vision is to improve the logistics and bring that manufacturing right into the patient,” Veiseh said. “That translates to substantial cost-cutting, better patient compliance and overall benefits to the patients. You just do it once, and it’s good for the rest of the year.”

He said HIV therapy would be simpler than his project to treat diabetes, because the implant would not have to monitor and respond to glucose levels. “The cells can just make the biologic,” Veiseh said. 

-30-

This news release can be found online at https://news.rice.edu/news/2022/hiv-drug-factory-implant-promises-once-year-therapy.

Follow Rice News and Media Relations via Twitter @RiceUNews.

Related materials:

Rice lab’s ‘drug factory’ implants cleared for human trials: https://news.rice.edu/news/2022/rice-labs-drug-factory-implants-cleared-human-trials

‘Drug factory’ implants eliminate ovarian, colorectal cancer in mice: https://news.rice.edu/news/2022/drug-factory-implants-eliminate-ovarian-colorectal-cancer-mice

Rice, Baylor developing implants to heal heart attack injuries: https://news.rice.edu/news/2022/rice-baylor-developing-implants-heal-heart-attack-injuries

Rice team creating insulin-producing implant for Type 1 diabetes: https://news.rice.edu/news/2021/rice-team-creating-insulin-producing-implant-type-1-diabetes

Veiseh Lab: https://veisehlab.rice.edu

Department of Bioengineering: https://bioengineering.rice.edu

George R. Brown School of Engineering: https://engineering.rice.edu

Image for download:

https://news-network.rice.edu/news/files/2022/11/0923_HIV-1-WEB-OMID-VEISEH.jpg

CAPTION: Omid Veiseh. (Credit: Jeff Fitlow/Rice University)

Located on a 300-acre forested campus in Houston, Rice University is consistently ranked among the nation’s top 20 universities by U.S. News & World Report. Rice has highly respected schools of Architecture, Business, Continuing Studies, Engineering, Humanities, Music, Natural Sciences and Social Sciences and is home to the Baker Institute for Public Policy. With 4,240 undergraduates and 3,972 graduate students, Rice’s undergraduate student-to-faculty ratio is just under 6-to-1. Its residential college system builds close-knit communities and lifelong friendships, just one reason why Rice is ranked No. 1 for lots of race/class interaction and No. 1 for quality of life by the Princeton Review. Rice is also rated as a best value among private universities by Kiplinger’s Personal Finance.



Share13Tweet8Share2ShareShareShare2

Related Posts

Unlocking Obesity: Multi-Omics and Machine Learning Insights

October 18, 2025

Tetanus Awareness Among Northern Morocco’s Healthcare Workers

October 18, 2025

Innovations in Non-Animal Scaffolds for Cultured Meat

October 18, 2025

ESMO 2025: Dual Targeted Therapy Demonstrates Potential in Treating Advanced Kidney Cancer After Prior Therapies

October 18, 2025

POPULAR NEWS

  • Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission

    1259 shares
    Share 503 Tweet 314
  • Stinkbug Leg Organ Hosts Symbiotic Fungi That Protect Eggs from Parasitic Wasps

    269 shares
    Share 108 Tweet 67
  • New Study Suggests ALS and MS May Stem from Common Environmental Factor

    111 shares
    Share 44 Tweet 28
  • New Study Indicates Children’s Risk of Long COVID Could Double Following a Second Infection – The Lancet Infectious Diseases

    102 shares
    Share 41 Tweet 26

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Unlocking Obesity: Multi-Omics and Machine Learning Insights

Tetanus Awareness Among Northern Morocco’s Healthcare Workers

Innovations in Non-Animal Scaffolds for Cultured Meat

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 65 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.